Antibiotics

It is produced by the strain of Streptomyces coeruleorubidus NRRL 18370. It's a Pacidamycin antibiotic. It has the activity against pseudomonas aeruginosa with MIC of 4-16 μg/mL. it has no effect on other gram-negative bacteria and gram-positive bacteria, and no effect on drug-resistant pseudomonas aeruginosa.

It is produced by the strain of Streptomyces coeruleorubidus NRRL 18370. It's a Pacidamycin antibiotic. It has the activity against pseudomonas aeruginosa with MIC of 4-16 μg/mL. it has no effect on other gram-negative bacteria and gram-positive bacteria, and no effect on drug-resistant pseudomonas aeruginosa.

It is produced by the strain of Str. paulus 273. It has anti-gram-positive bacterial effect, but also has weak anti-gram-negative bacterial effect. Paldimycin A has stronger antibacterial activity than Paldimycin B.

It is produced by the strain of Str. paulus 273. It has anti-gram-positive bacterial effect, but also has weak anti-gram-negative bacterial effect. Paldimycin A has stronger antibacterial activity than Paldimycin B.

It is produced by the strain of Str. paulus 273. It has anti-gram-positive bacterial effect, but also has weak anti-gram-negative bacterial effect. Paldimycin A has stronger antibacterial activity than Paldimycin B.

It is produced by the strain of Papularia sphaerosperma. It has strong anti-yeast effect, but no effect on filiform fungi, bacteria and protozoa. It has no cross-resistance with polyene antibiotics, Conocandin and azole antifungal chemotherapy drugs, but has partial cross-resistance with Echinocandin B. Among the four components, Papulacandin C has the strongest activity and Papulacandin D has the weakest activity.

It is produced by the strain of Papularia sphaerosperma. It has strong anti-yeast effect, but no effect on filiform fungi, bacteria and protozoa. It has no cross-resistance with polyene antibiotics, Conocandin and azole antifungal chemotherapy drugs, but has partial cross-resistance with Echinocandin B. Among the four components, Papulacandin C has the strongest activity and Papulacandin D has the weakest activity. The mechanism of B is to inhibit the synthesis of glucan in yeast cell wall.

It is produced by the strain of Papularia sphaerosperma. It has strong anti-yeast effect, but no effect on filiform fungi, bacteria and protozoa. It has no cross-resistance with polyene antibiotics, Conocandin and azole antifungal chemotherapy drugs, but has partial cross-resistance with Echinocandin B. Among the four components, Papulacandin C has the strongest activity and Papulacandin D has the weakest activity.

It is produced by the strain of Papularia sphaerosperma. It has strong anti-yeast effect, but no effect on filiform fungi, bacteria and protozoa. It has no cross-resistance with polyene antibiotics, Conocandin and azole antifungal chemotherapy drugs, but has partial cross-resistance with Echinocandin B. Among the four components, Papulacandin C has the strongest activity and Papulacandin D has the weakest activity.

It is produced by the strain of Streptomyces sp. B 8652. It has activity against gram-positive bacteria, negative bacteria and tumors, and no effect on fungal. It can inhibit tumor cells including GXF 251L, H640, LXFA 629L, MCF-7, MEXF 514L with IC70 of 0.9-6.7 μg/mL.

It is produced by the strain of Str. rimosus forma paromomycinus NRRL 2455. It's an aminoglycoside antibiotic. It has activity against gram-positive, negative bacteria, mycobacterium and protozoa. It has good curative effect for amebic dysentery and a few bacillary dysentery.

It is produced by the strain of Actinomadura paroosalo. It's a glycopeptide antibiotic. It has inhibitory effect on Staphylococcus aureus, Staphylococcus furfur, Staphylococcus hemolyticus and enterococcus faecalis.

It is produced by the strain of Actinomadura paroosalo. It's a glycopeptide antibiotic. It has inhibitory effect on Staphylococcus aureus, Staphylococcus furfur, Staphylococcus hemolyticus and enterococcus faecalis. Parvodicin C1 and C2 have stronger antibacterial effects than Parvodicin C3 and C4. The antibacterial activity of Parvodicin C is 1-4 times stronger than Tecomycin and 2-4 times stronger than vancomycin. The terminal branching activity of lipid chains is greater than straight chains (C1>C2>C3>C4, B1>B2), and the chain length is greater than short chains (C2>B). The half-life of Parvodicin C1 is longer in vivo than vancomycin and Archeomycin.

It is produced by the strain of Str. paulus 273. It has the effect of anti-gram-positive bacteria including Staphylococcus aureus, streptococcus pyogenes, streptococcus pneumoniae and so on.

It is produced by the strain of Str. paulus 273. It has the effect of anti-gram-positive bacteria including Staphylococcus aureus, streptococcus pyogenes, streptococcus pneumoniae and so on.

It is produced by the strain of Str. paulus 273. It has anti-gram-positive bacteria effect, and it has inhibitory effect on staphylococcus aureus resistant to penicillin, streptomycin, neomycin and macrolide antibiotics. The antibacterial activity of Paulomycin A, A1 and B are stronger than other components.

It is produced by the strain of Str. paulus 273. It has anti-gram-positive bacteria effect, and it has inhibitory effect on staphylococcus aureus resistant to penicillin, streptomycin, neomycin and macrolide antibiotics. The antibacterial activity of Paulomycin A, A1 and B are stronger than other components.

It is produced by the strain of Str. paulus 273. It has anti-gram-positive bacteria effect, and it has inhibitory effect on staphylococcus aureus resistant to penicillin, streptomycin, neomycin and macrolide antibiotics. The antibacterial activity of Paulomycin A, A1 and B are stronger than other components.

It is produced by the strain of Pelagiobacter variabilis.

It is produced by the strain of Pelagiobacter variabilis. It has the activity against gram-positive bacteria and gram-negative bacteria.